SCHEMBL1036705

SCHEMBL1036705

[NH]S(=O)(=O)c1c(Cl)cccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
AKR1B1 P15121 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2A6 P11509 1/20 0.39
TSHR P16473 2/20 0.38
LMNA P02545 1/20 0.38
ATM Q13315 2/20 0.38
CNR1 P21554 1/20 0.37
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
MCL1 Q07820 1/20 0.36
GAA P10253 1/20 0.36
MET P08581 1/20 0.36
SLC40A1 Q9NP59 1/20 0.36
POLB P06746 1/20 0.36
CES1 P23141 2/20 0.34
NSD2 O96028 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL181454 0.76 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1TDP1AKR1B1
SCHEMBL29209864 0.76 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1TDP1AKR1B1
SCHEMBL5607122 0.75 TSHR (0.53) ALDH1A1KMT2AMEN1TDP1AKR1B1
SCHEMBL440935 0.74 ALDH1A1 (0.44) ALDH1A1KMT2AMEN1TDP1AKR1B1
SCHEMBL6038587 0.74 CA1 (0.41) ALDH1A1KMT2AMEN1TSHRCNR1
SCHEMBL321973 0.74 ALDH1A1 (0.44) ALDH1A1KMT2AMEN1TDP1AKR1B1
SCHEMBL5020875 0.74 AKR1B1 (0.44) ALDH1A1KMT2AMEN1TDP1AKR1B1
SCHEMBL2251809 0.74 CXCR2 (0.46) ALDH1A1KMT2AMEN1TDP1AKR1B1
SCHEMBL1345186 0.72 HSD11B1 (0.46) ALDH1A1AKR1B1TSHRLMNAGAA
Hydrochloric Acid SCHEMBL27552065 0.72 ALDH1A1 (0.42) ALDH1A1KMT2AMEN1TDP1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2276731-A1 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 Boehringer Ingelheim International GmbH (DE) 2011-01-26 EP disclosed
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 ALDH1A1 2902/4885KMT2A 4190/4885MEN1 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.